Jaguar Health's Crofelemer Trial for MVID Receives FDA Support for Extension Phase

Jaguar Health's clinical trial of crofelemer for treating Microvillus Inclusion Disease (MVID) has received FDA feedback supporting an extension phase. The trial aims to evaluate the safety and efficacy of a novel crofelemer powder formulation in pediatric patients with intestinal failure due to MVID. The extension phase will allow patients to continue treatment with crofelemer for further assessment of clinical benefit through reduction of parenteral support requirements.